Tardive dyskinesia (TD) is an involuntary movement disorder predominantly the result of long-term neuroleptic administration. Several factors have been studied with conflicting results. In this paper, the authors compare a group of 17 TD patients with 17 non-TD controls to delineate possible etiological factors in the development of this syndrome. Factors like total neuroleptic and anti-parkinsonian medication intake and organicity were not different in the groups. Only drug-free periods in the past history of TD patients were found to be statistically more significant (P < 0.025) in these patients than in non-TD controls.
References
1.
SchoneckerM. In: DeVeaugh-GeissJ., ed. Tardive dyskinesia and involuntary movement disorders.John Wright: PSG, Boston, 1982: 199–201.
2.
SmithJ.M., OswaldW.T., KucharskiL.T.. Tardive dyskinesia: age and sex differences in hospitalized schizophrenics.Psychopharmacology1978; 58: 207–211.
3.
SmithJ.M., BaldessariniR.J.Changes in prevalence, severity and recovery in tardive dyskinesia with age.Arch Gen Psychiatry1980; 37: 1368–1373.
4.
SimpsonG.M., VargaE., LeeJ.H.. Tardive dyskinesia and psychotropic drug history.Psychopharmacology1978; 58: 117–124.
5.
PerrisC., DimitiejevicP., JacobssonL.. Tardive dyskinesia in psychiatric patients treated with neuroleptics.Br J Psychiatry1980; 168: 215–218.
6.
ChienC-P, Ross-TownsendA., DonnellyM.Past history of drug and somatic treatments in tardive dyskinesia. In: FannW.E., SmithR.C., DavisJ.M., eds. Tardive dyskinesia: research and treatment.New York: SP Medical and Scientific Books, 1982: 297–308.
7.
SmithR.C., StrizichM., KlassD.History of neuroleptic drugs and tardive dyskinesia. In: FannW.E., SmithR.C., DavisJ.M., eds. Tardive dyskinesia: research and treatment.New York: SP Medical and Scientific Books, 1982: 309–314.
8.
BrancheyM.H., RichardsonM.A., SiegelC.Psychotropic drug history and tardive dyskinesia.Psychopharmacol Bull1983; 19: 120–122.
9.
YassaR., AnanthJ., CordozoS.. Tardive dyskinesia in an outpatient population: prevalence and predisposing factors.Can J Psychiatry1983; 28: 391–394.
10.
GuyW.ECDEU Assessment manual for psychopharmacology.US Dept of Health, Education and Welfare197, 1976: 534–537.
11.
SchoolerN., KaneJ.M.Research diagnosis for tardive dyskinesia.Arch Gen Psychiatry1982; 39: 486–487.
12.
DavisJ.M.Dose equivalence of antipsychotic drugs.J Psychiatr Res1974; 11: 65–69.
13.
SnyderS.H., GreenbergD., YamamuraH.I.Antischizophrenic drugs and brain cholinergic receptors.Arch Gen Psychiatry1974; 31: 58–61.
14.
JesteD.V., PotkinS.G., SinkaS.. Tardive dyskinesia: reversible and persistent.Arch Gen Psychiatry1979; 36: 585–590.
15.
KaneJ.M., SmithJ.M.Tardive dyskinesia: prevalence and risk factors 1959 to 1979.Arch Gen Psychiatry1982; 39: 473–481.
16.
JesteD.V., WyattR.J.Understanding and treating tardive dyskinesia.New York: The Guilford Press, 1982: 81–93.